

November 13, 2018

The Manager – Listing  
**BSE Limited,**  
1<sup>st</sup> Floor, New Trading Ring  
Rotunda Building, P J Towers, Dalal Street, Fort,  
Mumbai 400001

The Manager – Listing  
**National Stock Exchange of India Ltd.**  
Exchange plaza, 5<sup>th</sup> Floor, Plot No.C/1, G Block  
Bandra-Kurla Complex, Bandra (E),  
Mumbai 400051

Dear Sir(s),

**Sub: Outcome of the Board Meeting held on Tuesday, November 13, 2018**

**Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN**

At the Board Meeting of the Company held on Tuesday, November 13, 2018, the Board of Directors considered and approved the Unaudited Financial Results of the Company for the quarter ended September 30, 2018. The said Unaudited Financial Results together with the Limited Review report of the Statutory Auditors dated November 13, 2018 are enclosed herewith.

Please take the same on record.

Thanking you,

For AstraZeneca Pharma India Limited

  
**Pratap Rudra**  
Company Secretary & Legal Counsel



AstraZeneca Pharma India Limited  
Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045  
Statement of Unaudited financial results for the quarter and six months ended 30 September 2018

SI No.	Particulars	Rs in lakhs except for earnings per share data					
		3 months ended 30/09/2018  (Unaudited)	Previous 3 months ended 30/06/2018  (Unaudited)	Corresponding 3 months ended in the previous year 30/09/2017  (Unaudited)	6 months ended 30/09/2018  (Unaudited)	6 months ended 30/09/2017  (Unaudited)	Previous year ended 31/03/2018  (Audited)
1	<b>Revenue</b>						
	a) Revenue from operations	16,136.08	16,143.68	16,425.83	32,279.76	29,272.41	57,198.92
	b) Other income	335.45	342.28	249.57	677.73	714.98	1,224.76
	<b>Total revenue</b>	<b>16,471.53</b>	<b>16,485.96</b>	<b>16,675.40</b>	<b>32,957.49</b>	<b>29,987.39</b>	<b>58,423.68</b>
2	<b>Expenses</b>						
	(a) Cost of materials consumed	946.41	1,687.33	312.40	2,633.74	860.17	2,788.01
	(b) Purchase of stock-in-trade	2,736.24	1,999.45	4,778.19	4,735.69	10,622.15	20,421.17
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	1,590.00	1,648.04	254.76	3,238.04	(1,622.43)	(5,099.57)
	(d) Excise duty	-	-	-	-	98.50	98.50
	(e) Employee benefits expense	4,495.17	4,307.28	3,640.19	8,802.45	7,134.07	15,353.09
	(f) Depreciation and amortisation expense	367.38	355.04	374.85	722.42	745.65	1,473.75
	(g) Selling, marketing and distribution expense	1,168.43	2,862.02	1,526.49	4,030.45	2,712.40	7,280.51
	(h) Other expenses	3,723.52	2,711.61	2,348.84	6,435.13	5,280.90	11,728.21
	(i) Finance cost	-	-	-	-	-	-
	<b>Total expenses</b>	<b>15,027.15</b>	<b>15,570.77</b>	<b>13,235.72</b>	<b>30,597.92</b>	<b>25,831.41</b>	<b>54,043.67</b>
3	<b>Profit before exceptional and extraordinary items and tax (1-2)</b>	<b>1,444.38</b>	<b>915.19</b>	<b>3,439.68</b>	<b>2,359.57</b>	<b>4,155.98</b>	<b>4,380.01</b>
4	Exceptional items	-	-	-	-	-	-
5	<b>Profit before extraordinary items and tax (3+4)</b>	<b>1,444.38</b>	<b>915.19</b>	<b>3,439.68</b>	<b>2,359.57</b>	<b>4,155.98</b>	<b>4,380.01</b>
6	Extraordinary items	-	-	-	-	-	-
7	<b>Profit before tax (5+6)</b>	<b>1,444.38</b>	<b>915.19</b>	<b>3,439.68</b>	<b>2,359.57</b>	<b>4,155.98</b>	<b>4,380.01</b>
8	<b>Tax expense</b>						
	- Current tax	437.87	263.47	698.77	701.34	851.37	899.74
	- Deferred tax	93.35	12.38	2.43	105.73	(13.60)	888.79
	<b>Total tax expense</b>	<b>531.22</b>	<b>275.85</b>	<b>701.20</b>	<b>807.07</b>	<b>837.77</b>	<b>1,788.53</b>
9	<b>Profit for the period (7-8)</b>	<b>913.16</b>	<b>639.34</b>	<b>2,738.48</b>	<b>1,552.50</b>	<b>3,318.21</b>	<b>2,591.48</b>
10	<b>Other comprehensive income, net of income tax</b>						
	A. Items that will not be reclassified to profit or loss	(36.62)	166.51	(9.43)	129.89	52.93	(227.99)
	B. Items that will be reclassified to profit or loss	-	-	-	-	-	-
	<b>Total other comprehensive income, net of income tax</b>	<b>(36.62)</b>	<b>166.51</b>	<b>(9.43)</b>	<b>129.89</b>	<b>52.93</b>	<b>(227.99)</b>
	<b>Total comprehensive income for the period (9+10)</b>	<b>876.54</b>	<b>805.85</b>	<b>2,729.05</b>	<b>1,682.39</b>	<b>3,371.14</b>	<b>2,363.49</b>
11	<b>Earnings per equity share of Rs 2/- each (basic and diluted)</b>	<b>3.65</b>	<b>2.56</b>	<b>10.95</b>	<b>6.21</b>	<b>13.27</b>	<b>10.37</b>




*[Handwritten signature]*

**AstraZeneca Pharma India Limited**  
**Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045**  
**Statement of Unaudited financial results for the quarter and six months ended 30 September 2018**

**Notes:**

- 1 The Statutory Auditors have carried out a Limited Review of the financial results for the quarter and six months ended 30 September 2018 including Balance sheet as at 30 September 2018 (the 'statement') as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The statement has been reviewed by the Audit Committee and subsequently approved by the Board of Directors of the Company at their respective meetings held on 13 November 2018.
- 2 The Statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- 3 Ind AS 115 'Revenue from contracts with customers' mandatory for reporting periods beginning on or after 1 April 2018, replaces existing revenue recognition requirements. Under the modified retrospective approach, there were no significant adjustments required to the retained earnings as at 1 April 2018. The adoption of the standard did not have any impact on the financial results for the quarter and for the six months ended 30 September 2018.
- 4 The Company has identified 'Healthcare Segment' as its only reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly no segment information has been provided.
- 5 As previously disclosed, by way a of letter dated 1 March 2014, AstraZeneca Pharmaceuticals AB, the promoter of the Company had proposed a voluntary delisting of the Company's equity shares from the National Stock Exchange and the Bombay Stock Exchange. Such proposed delisting is subject to an on-going inquiry with SEBI and that inquiry has not yet been resolved. In any event, based on the passage of time, any potential future proposal for voluntary delisting of the Company would need to be conducted de novo.
- 6 Previous period's figures have been regrouped/reclassified, where necessary, to conform with the current period's presentation for the purpose of comparability.

**By Order of the Board of Directors  
For AstraZeneca Pharma India Limited**

  
**Gagandeep Singh Bedi  
Managing Director**

**Place: New Delhi  
Date: 13 November 2018**





**AstraZeneca Pharma India Limited**  
**Regd Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045**

**Unaudited Statement of assets and liabilities as at 30 September 2018**

		(Rs in lakhs)	
SI.No.	Balance Sheet	As at 30 September 2018 (Unaudited)	As at 31 March 2018 (Audited)
	<b>ASSETS</b>		
1	<b>Non-current assets</b>		
	(a) Property, plant and equipment	7,320.23	7,546.02
	(b) Capital work-in-progress	712.58	357.27
	(c) Financial Assets		
	(i) Investments	-	-
	(ii) Loans	280.78	263.85
	(iii) Current tax assets	1,796.75	2,356.04
	(iv) Deferred tax assets	2,934.72	3,255.29
	(d) Other non-current assets	102.23	184.10
	<b>Sub-total - Non-current assets</b>	<b>13,147.29</b>	<b>13,962.57</b>
2	<b>Current assets</b>		
	(a) Inventories	7,886.47	11,315.10
	(b) Financial Assets		
	(i) Trade receivables	6,007.91	5,462.54
	(ii) Cash and cash equivalents	18,744.38	11,398.24
	(iii) Bank balances other than (ii) above	5.75	1,194.00
	(iv) Loans	95.69	123.94
	(v) Other financial current assets	1,017.76	353.71
	(c) Other current assets	1,816.32	2,243.82
	<b>Sub-total - Current assets</b>	<b>35,574.28</b>	<b>32,091.35</b>
	<b>TOTAL - ASSETS</b>	<b>48,721.57</b>	<b>46,053.92</b>
1	<b>EQUITY AND LIABILITIES</b>		
	<b>Equity</b>		
	(a) Equity Share capital	500.00	500.00
	(b) Other Equity	25,846.13	24,193.18
	<b>Sub-total - Shareholders' funds</b>	<b>26,346.13</b>	<b>24,693.18</b>
	<b>LIABILITIES</b>		
	<b>Non-current liabilities</b>		
	(a) Financial Liabilities		
	(i) Other financial liabilities	-	-
	(b) Other non-current liabilities	-	-
	(c) Provisions	208.99	665.77
	<b>Sub-total - Non-current liabilities</b>	<b>208.99</b>	<b>665.77</b>
2	<b>Current liabilities</b>		
	(a) Financial Liabilities		
	(i) Trade payables		
	Total outstanding dues of micro enterprises and small enterprises	9.04	2.00
	Total outstanding dues of creditors other than micro enterprises and small enterprises	14,971.49	12,717.87
	(ii) Other financial liabilities	2,936.34	3,185.11
	(b) Other current liabilities	622.16	756.36
	(c) Provisions	3,092.08	3,498.12
	(d) Current tax liability	535.34	535.51
	<b>Sub-total - Current liabilities</b>	<b>22,166.45</b>	<b>20,694.97</b>
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>48,721.57</b>	<b>46,053.92</b>



*Jagan*

# Price Waterhouse & Co Chartered Accountants LLP

The Board of Directors  
AstraZeneca Pharma India Limited  
Block N1, 12th Floor,  
Manyata Embassy Business Park,  
Rachenahalli, Outer Ring Road,  
Bengaluru 560045

1. We have reviewed the unaudited financial results of AstraZeneca Pharma India Limited (the "Company") for the quarter ended September 30, 2018 and the half year ended September 30, 2018 which are included in the accompanying 'Statement of unaudited results for the quarter and six month ended September 30, 2018' and the statement of assets and liabilities as that date together with the notes thereon (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations, 2015"), which has been initialled by us for identification purposes. The Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse & Co Chartered Accountants LLP  
Firm Registration Number: 304026E/ E-300009



Pradip Kanakia  
Partner  
Membership Number: 039985

Place: Bengaluru  
Date: November 13, 2018

Price Waterhouse & Co Chartered Accountants LLP, 5th Floor, Tower 'D', The Millenia, 1 & 2 Murphy Road  
Ulsoor, Bangalore-560 008  
T: +91 (80) 4079 5000, F: +91 (80) 4079 5222

Registered office and Head office: Plot No. Y-14, Block EP, Sector V, Salt Lake Electronic Complex, Bidhan Nagar, Kolkata 700 091

Price Waterhouse & Co. (a Partnership Firm) converted into Price Waterhouse & Co Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-4362) with effect from July 7, 2014. Post its conversion to Price Waterhouse & Co Chartered Accountants LLP, its ICAI registration number is 304026E/E-300009 (ICAI registration number before conversion was 304026E)